In less than one hour, the Xpert MRSA/SA skin and soft tissue (SSTI) test processes specimens from suspected skin and soft tissue infection swabs to determine if a patient is infected with Methicillin-resistant Staphylococcus aureus (MRSA) or SA, the company said.
The new test runs on Cepheid’s GeneXpert System, a healthcare associated infection molecular testing platform. The availability of the Xpert MRSA/SA SSTI test is expected to empower Canadian physicians and surgeons with a new tool to aid in selecting the most effective antibiotic therapy to improve patient management.
Xpert MRSA/SA SSTI is Cepheid’s fifth test to receive a Health Canada medical device license. Xpert MRSA/SA blood culture and Xpert HemosIL are currently under review.